Trials / Terminated
TerminatedNCT03239860
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
A Long-Term International, Extension of Study GNC-003 With GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- GeNeuro SA · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis. The study assesses the long-term safety of GNbAC1 in patients with RRMS and the long-term efficacy of GNbAC1 in terms of MRI outcomes, relapse rate, disability and disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GNbAC1 Monoclonal Antibody | Monthly IV |
Timeline
- Start date
- 2017-06-06
- Primary completion
- 2018-11-14
- Completion
- 2018-11-14
- First posted
- 2017-08-04
- Last updated
- 2020-10-20
Locations
12 sites across 12 countries: Bulgaria, Croatia, Czechia, Estonia, Germany, Hungary, Italy, Poland, Russia, Serbia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT03239860. Inclusion in this directory is not an endorsement.